HaystackAnalytics provides the Universal Infectious Diseases (UID) test, an NGS‑based, culture‑free assay that detects over 1,200 bacterial and fungal pathogens and their antibiotic‑resistance genes from clinical samples in about 12 hours. The test delivers species‑ and genus‑level identification with automated bioinformatics reports, enabling labs and hospitals to quickly select targeted therapies for sepsis and other acute infections.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current infectious disease diagnostics rely on culture-based methods that take days to weeks and molecular panels that cover only a limited number of pathogens, delaying appropriate treatment and increasing mortality, especially for high‑risk groups such as sepsis patients, cancer, diabetes, and immunocompromised individuals.
Solution
HaystackAnalytics offers the Universal Infectious Diseases (UID) test, an NGS‑based, culture‑free assay that detects over 1,200 bacterial and fungal pathogens directly from clinical samples within approximately 12 hours. The test provides species‑ and genus‑level identification together with antibiotic‑resistance gene (ARG) profiling, enabling clinicians to select targeted therapy promptly. By eliminating the need for lengthy culture steps and expanding pathogen coverage far beyond conventional panels, the UID test accelerates diagnosis for sepsis and other acute infections. The platform integrates automated bioinformatics pipelines that translate raw sequencing data into actionable reports for diagnostic labs and hospitals, supporting faster clinical decision‑making and improved patient outcomes.
Target Audience
Primary customers are clinical laboratories, hospitals, and diagnostic centers that need rapid, broad‑spectrum infectious disease testing for sepsis management and high‑risk patient populations.
Features
- NGS‑based assay covering >1,200 bacterial and fungal pathogens in a single run
- Culture‑free workflow delivering results in ~12 hours
- Comprehensive antibiotic‑resistance gene (ARG) profiling for informed antimicrobial selection
- Species‑ and genus‑level identification with automated bioinformatics reporting
- Compatible with existing diagnostic laboratory infrastructure; no specialized equipment required
- Cloud‑enabled data management ensuring secure storage and easy access to reports